Optimi Health Completes MDMA Export for PTSD Treatment Under Australia's Authorised Prescriber Scheme

Executive Summary

• Optimi Health Corp. completed its first export of 1,000 MDMA capsules (60 mg) to Australia under the Authorised Prescriber Scheme.
• The shipment supports over 300 authorised PTSD treatment sessions and is part of a real‑world evidence study conducted by the Australian National University.
• The export follows receipt of both Australian import permits and Health Canada export permits, confirming regulatory compliance for international distribution.

Key Details

• Export Quantity: 1,000 MDMA capsules, each containing 60 mg of MDMA.
• Therapeutic Use: Intended for authorised clinical programs treating Post‑Traumatic Stress Disorder (PTSD) via MDMA‑assisted therapy.
• Treatment Capacity: Sufficient to support >300 PTSD treatment sessions under standard protocols.
• Regulatory Approvals: Export authorized by Health Canada; Australian import permits obtained; Australian pharmacy partner acts as importer of record and national distributor.
• Clinical Data Collection: Patient‑Reported Outcomes (PROs) are being gathered by the Australian National University to build a comprehensive real‑world evidence dataset on MDMA‑assisted therapy for PTSD.
• Reimbursement Framework: The Australian Department of Veterans' Affairs offers reimbursement for eligible veterans receiving psychedelic‑assisted therapy under program requirements.
• Market Context: Australian Bureau of Statistics estimates 5–6 % annual prevalence of PTSD (~1.3–1.5 million people), with higher rates among veterans and first responders.
• Contact Information:
• CEO Dane Stevens – (778) 761‑4551, [email protected]
• Investor Relations – Lucas A. Zimmerman, MZ Group – (262) 357‑2918, [email protected]

Notable Quotes

(No direct quotes provided in the release.)